Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02054091
Other study ID # H-3-2013-136
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2014
Est. completion date January 2017

Study information

Verified date January 2019
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Feeding preterm infants is of great challenge in the NICUs. Mother's own milk is considered as the best for the digestive system followed by donor milk. Preterm infant formula is related to more feeding problems and other gut complications in these babies, such as necrotizing enterocolitis. Bovine colostrum contains higher amounts of protein, growth factors and immuno-regulatory components (e.g. immunoglobulins), which has been used in many other situations to promote health. The investigators plan to give bovine colostrum to preterm infants with birth weights between 1000 and 1800 g, or born between 27+0 and 32+6 weeks of gestational age, in order to promote feeding and intestinal health in these babies. This current study is a feasibility pilot study and the investigators hypothesized that supplementing BC to MM (if available) is safe and tolerable when used within the first 10-14 days of life in preterm infants.


Description:

Preterm birth (<37 weeks gestation) occurs in 10% of all pregnancies worldwide and the optimal way to feed a newborn preterm infant, when breast-feeding is impossible, is not clear. Excessive enteral feeding predisposes to various complications and necrotizing enterocolitis (NEC) that occur in 7% of preterm infants born with less than 1500 g body weight. Early feeding with small volumes of milk is applied to promote GIT maturation and add some nutrients and energy. It is assumed that early feeding allows more rapid advancement to full enteral feeding (EN, e.g 120-160 ml/kg/d) and weaning from parenteral nutrition (PN). This is important to reduce PN-related complications (e.g. sepsis) and to better stimulate body and organ (e.g. gut, brain) development. However, it remains unclear what is the best milk diet when mother's own milk (MM) is not available. Infant formula (IF) and banked human donor milk (DM) are the most frequently used alternatives to MM. MM is superior to IF in promoting feeding tolerance, intestinal function, and NEC resistance in preterm infants. Feeding with DM is also believed to be beneficial, relative to IF, although this pasteurized milk obtained from mothers later in lactation may be less beneficial, relative to the first milk, colostrum. There are differences in the amount and composition between human colostrum and bovine colostrum (BC), but relative to mature human milk, BC contains higher amounts of protein, growth factors and immuno-regulatory components (e.g. immunoglobulins). Large amount of protein in BC provides higher enteral protein intake and may enable a reduction in the use of PN and central venous catheters, and hereby reduced risk of infection. Also this may lead to reduced weight loss and improved growth of the brain and the body. In addition, maturational and NEC-protective effects of BC have repeatedly been documented in preterm pigs when BC is used as the first diet after birth. The investigators therefore plan to investigate whether using BC as nutrition for preterm infants in the first weeks of life is safe, tolerable, and helps to provide nutrients and gut maturation , when MM is not in sufficient amounts or not available.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date January 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group N/A to 1 Day
Eligibility Inclusion Criteria:

- FWCH & SBMCH: Preterm infants with birth weights between 1000 and 1800 g, delivered at FWCH & SBMCH, or transferred from other hospitals within 24 h of birth and without any enteral feeding.

RH & HH: Preterm infants less than 24 hours of age, between 27+0 and 32+6 weeks of gestation, delivered at RH &HH , or transferred from other hospitals within the first 24 h after birth.

- Signed parental consent

Exclusion Criteria:

- Major congenital anomalies or birth defects

- Congenital infection

- Perinatal asphyxia

- Gestational age at birth < 28 weeks (FWCH & SBMCH)

- Extremely SGA infant (weight SD score < -3 SD)

- Need for mechanical ventilation or cardiovascular support before first BC feeding

Study Design


Intervention

Dietary Supplement:
Bovine colostrum
The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by ?-irradiation.

Locations

Country Name City State
China Foshan Women and Children's Hospital (FWCH) Foshan Guangdong
China Shenzheng Baoan Maternity and Child Healthcare Hospital (SBMCH) Shenzhen Guangdong
Denmark Rigshospitalet (RH) Copenhagen
Denmark Hvidovre Hospital (HH) Hvidovre

Sponsors (1)

Lead Sponsor Collaborator
Per Torp Sangild

Countries where clinical trial is conducted

China,  Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Routine blood tests Routine blood tests include blood gas analysis, liver enzymes, BUN, creatinine, Na, K, and phosphate. On day 7±1 at RH & HH and on day 7±1 and 14±1 at FWCH & SBMCH
Other Plasma amino acid composition Plasma amino acids will be analyzed at each hospital to investigate whether BC feeding provides a normal range of plasma amino acid pattern. On day 7±1 at RH & HH and on day 7±1 and 14±1 at FWCH & SBMCH
Other Plasma bovine IgG level The concentration of intact bovine IgG will be measured in the plasma samples from the participants who receive BC supplementation, in order to investigate how much intact bovine IgG is absorbed from the intestine and circulating in the blood. This will only be measured in the participants at RH due to practical reasons. On day 7±1 at RH for phase A and B
Other Fecal bovine IgG The concentration of intact bovine IgG will be measured in the fecal samples from participants who receive BC supplementation, in order to investigate whether bovine IgG can survive digestion. On day 7±1 at RH & HH and day 7±1 and 14±1 days
Other Fecal short chain fatty acids (SCFAs) Fecal SCFAs will be measured as an indicator of bacterial fermentation of the unabsorbed nutrients in the colon. On day 7±1 at RH & HH and day 7±1 and 14±1 days
Other Fecal microbiota composition Microbiota composition in fecal samples will be determined using non-culture-based techniques On day 7±1 at RH & HH and day 7±1 and 14±1 days
Primary The primary outcome is the tolerability of bovine colostrum feeding The main purpose of this feasibility pilot study is to investigate whether preterm infants can tolerate bovine colostrum as their first nutrition supplemented to mother's own milk (if available). Presence of feeding intolerance is defined as at any time when feeding is withheld by the neonatologists from day 1-7 and from day 8-14. From birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Secondary Anthropometry data Body weight, body length, and head circumference are measured as anthropometry data Weekly measured from birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Secondary Days to regain birth weight From birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Secondary Days on parenteral nutrition Days on PN are the total number of days that a participant receiving any i.v. nutrients other than glucose. From birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Secondary Time to full enteral feeding Full enteral feeding is defined as participants receiving 160ml/kg/d at copenhagen site, or more than 120 ml/kg/d at Chinese sites for a consecutive period of 72 hours. From birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Secondary Combined incidence of serious infections and NEC Serious infections/NEC includes sepsis and meningitis, according the diagnostic criteria at each hospital, and Bell stage II or III NEC. From birth until the recruited subject reaches postmenstrual age at 37 weeks or discharge home, whichever comes first
Secondary Plasma citrulline level Citrulline concentration is measured in plasma as a biomarker for absorptive enterocyte mass and/or function On day 7±1 at RH & HH and on day 7±1 and 14±1 at FWCH & SBMCH
Secondary Lactase activity and intestinal permeability Lactase activity and intestinal permeability is measured non-invasively by measuring the urinary ratio of lactulose/lactose, and lactulose/mannitol after the three sugars are administered. On day 7±1
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3